2Siewert JR,Stein HJ,Sendler A,et al:Esophageal cancer:Clinical managment,in Kelson D,Daly JM,Kern SE,et al(eds):Gastrointestinal Oncology:Principles and Practice[M].Philadelphia,PA,Lippincott Williams & Wilkins,2002:276-278.
3Anderson SE,O'Reilly EM,Kelsen DP,et al.Phase II trial of 96-hour paclitaxel in previously treated patients with esophageal cancer[J].Cancer Invest,2003,21:512-516.
4Bleiberg H,Conroy T,Paillot B,et al.Randomized phase II study of cisplatin and 5-fluorouracil(5-FU)versus cisplatin alone in advanced squamous cell oesophageal cancer[J].Eur J Cancer,1997,33:1216-1220.
5Ilson D,Forastier AA,Arquette M,et al.A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus[J].Cancer J,2000,6:316-323.
6Polee MB,Eskens FA,van der Burg ME,et al.Phase II study of biweekly administration of paclitaxel and cisplatin in patierns with advanced oesophageal cancer[J].Br J Cancer,2002,86(5):669-73.
7Ildson DH.Phase II trail of weekly irinotecan/cisplatin in advanced esophageal cancer[J].Oncology(Williston Park),2004,18(14 Suppl14):22-25.
8Ajani JA,Baker J,Pisters PW,et al.CPT-11 plus cisplatin in patients with advanced,untreated gastric or gastroesophageal junction carcinoma:results of a phase II study[J].Cancer,2002,94(3):641-646.
9Urbs SG,Ghansky K,Van Veldhuizen PJ,et al.Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma:a Southwest Oncology Group Study[J].Invest New Drugs,2004,22(1):91-97.
10Kroep JR,Pinedo HM,Giaccone U,et al.Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer[J].Ann Oncol,2004,15(2):230-235.
6MANABU EMI, JUN HIHARA, YOICHI HAMAI, et al. Neoadjuvant chemoradiotherapy with doeetaxel, cisplatin, and 5- fluorouracil for esophageal cancer [ J ]. Cancer Chemother Pharmacol,2012,69(6) : 1499 - 1505.
7SHAH MA,JHAWER M,LEFKOWITZ RA,et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma [ J ]. J Clin Oncol,2011,29 (7) : 868 - 874.
